---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-090831"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2024-10-25T23:59:59+00:00"
generated_at: "2026-05-30T10:08:17.825664+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# CERO Therapeutics receives Nasdaq delisting notice; stock price at $0.10 or less

## Summary
- Nasdaq determined to delist CERO common stock due to closing bid price ≤$0.10 for 10 consecutive days.
- Company has until Oct 31, 2024 to appeal; hearing request will stay suspension pending panel decision.
- Company plans to propose reverse stock split at Nov 11 special meeting to regain compliance, but approval uncertain.
- Prior Bid Price Cure Period until Jan 15, 2025 is rendered unavailable by Low Priced Stocks Rule.

## SEC filing metadata
- accession: 0001213900-24-090831
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2024-10-25T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390024090831/0001213900-24-090831-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390024090831/ea0218621-8k_cerothe.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-090831
- JSON: https://secwatch.observer/filing/0001213900-24-090831.json
- Plain text: https://secwatch.observer/filing/0001213900-24-090831.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.